Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT)

被引：0
|
作者：
Gordon, Michael S.
Kluger, Harriet M.
Shapiro, Geoffrey
Kurzrock, Razelle
Edelman, Gerald
Samuel, Thomas A.
Moussa, Ali H.
Ramies, David A.
Laird, A. Douglas
Schimmoller, Frauke
Shen, Xiaodong
Daud, Adil
机构：
[1] Pinnacle Oncol Hematol, Scottsdale, AZ USA
[2] Yale Canc Ctr, New Haven, CT USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Texas Oncol, Irving, TX USA
[6] Georgia Hlth Sci Univ, Augusta, GA USA
[7] Canc Care Associates, Tulsa, OK USA
[8] Exelixis, San Francisco, CA USA
[9] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8531
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT).
    Hellerstedt, Beth A.
    Edelman, Gerald
    Vogelzang, Nicholas J.
    Kluger, Harriet M.
    Yasenchak, Christopher A.
    Shen, Xiaodong
    Ramies, David A.
    Gordon, Michael S.
    Lara, Primo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT)
    Winer, Eric P.
    Tolaney, Sara
    Nechushtan, Hovav
    Berger, Raanan
    Kurzrock, Razelle
    Ron, Ilan-Gil
    Schoffski, Patrick
    Awada, Ahmad
    Yasenchak, Christopher A.
    Burris, Howard A.
    Ramies, David A.
    Rafferty, Teresa
    Shen, Xiaodong
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT)
    Verslype, Chris
    Cohn, Allen Lee
    Kelley, Robin Katie
    Yang, Tsai-Shen
    Su, Wu-Chou
    Ramies, David A.
    Lee, Yihua
    Shen, Xiaodong
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT)
    Cohn, Allen Lee
    Kelley, Robin Katie
    Yang, Tsai-Shen
    Su, Wu-Chou
    Verslype, Chris
    Ramies, David A.
    Lee, Yihua
    Shen, Xiaodong
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [5] Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT).
    Buckanovich, R. J.
    Berger, R.
    Sella, A.
    Sikic, B. I.
    Shen, X.
    Ramies, D. A.
    Smith, D. C.
    Vergote, I. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Cabozantinib (XL184) in Patients with Metastatic Breast Cancer: Results from a Phase 2 Randomized Discontinuation Trial
    Tolaney, S. M.
    Nechushtan, H.
    Berger, R.
    Kurzrock, R.
    Ron, I. G.
    Schoffski, P.
    Awada, A.
    Yasenchak, C. A.
    Burris, H. A.
    Ramies, D. A.
    Shen, X.
    Winer, E. P.
    CANCER RESEARCH, 2011, 71
  • [7] Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT)
    Daud, Adil
    Kluger, Harriet M.
    Edelman, Gerald
    Gordon, Michael S.
    Schimmoller, Frauke
    Weitzman, Aaron
    Samuel, Thomas A.
    Moussa, Ali H.
    Flaherty, Keith
    Shapiro, Geoffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors.
    Gordon, M. S.
    Vogelzang, N. J.
    Schoffski, P.
    Daud, A.
    Spira, A. I.
    O'Keeffe, B. A.
    Rafferty, T.
    Lee, Y.
    Berger, R.
    Shapiro, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.
    Hussain, M.
    Smith, M. R.
    Sweeney, C.
    Corn, P. G.
    Elfiky, A.
    Gordon, M. S.
    Haas, N. B.
    Harzstark, A. L.
    Kurzrock, R.
    Lara, P.
    Lin, C.
    Sella, A.
    Small, E. J.
    Spira, A. I.
    Vaishampayan, U. N.
    Vogelzang, N. J.
    Scheffold, C.
    Ballinger, M. D.
    Schimmoller, F.
    Smith, D. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Phase 2 randomized discontinuation trial (RDT) of XL184 in patients (pts) with advanced solid tumors
    Schoeffski, P.
    Sgroi, M.
    Burris, H. A.
    Lutzky, J.
    Rearden, T.
    Sikic, B.
    Stephenson, J., Jr.
    Elhardt, D.
    Lee, Y.
    Kurzrock, R.
    EJC SUPPLEMENTS, 2010, 8 (07): : 117 - 117
12345